Improved Survival with Bevacizumab in Advanced Cervical Cancer

BACKGROUND: Vascular endothelial growth factor (VEGF) promotes angiogenesis, a mediator of disease progression in cervical cancer. Bevacizumab, a humanized anti-VEGF monoclonal antibody, has single-agent activity in previously treated, recurrent disease. Most patients in whom recurrent cervical canc...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Tewari, Krishnansu S., Sill, Michael W., Long, Harry J., Penson, Richard T., Huang, Helen, Ramondetta, Lois M., Landrum, Lisa M., Oaknin, Ana, Reid, Thomas J., Leitao, Mario M., Michael, Helen E., Monk, Bradley J.
格式: Artigo
語言:Inglês
出版: 2014
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4010094/
https://ncbi.nlm.nih.gov/pubmed/24552320
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1309748
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍